Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-10-05 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2022-10-05 English
Submits New Information to FDA IND File for SR-aGVHD 3 pages 167.0KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Mesoblast has submitted new information to the FDA in response to a Complete Response Letter (CRL) related to a Biologics License Application (BLA) for a specific treatment. It discusses regulatory interactions, clinical data submissions, and forward-looking statements. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a full annual or quarterly report, nor is it a transcript, audit report, or governance document. It is an update on regulatory filings and interactions with the FDA, typical of a Regulatory Filing (RNS). The length is moderate but the content is clearly an announcement rather than a full report or detailed financial disclosure. Therefore, the best classification is Regulatory Filings (RNS).
2022-10-02 English
REGISTRATION STATEMENT
Regulatory Filings
2022-09-30 English
6-K
Regulatory Filings
2022-09-23 English
Change of Director's Interest Notice 2 pages 223.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the transaction, the nature of the transaction (on-market purchase), and dates. This is a clear report of personal share transactions by a company director. The document length is 3939 characters, which is typical for such notices. There is no indication that this is an annual report, earnings release, or any other type of report. Therefore, the document fits the definition of 'Director's Dealing' (DIRS).
2022-09-19 English
6-K
Regulatory Filings
2022-09-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.